ArticleThe Journal of experimental medicine2015

Selective interleukin-1 receptor-associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy.

Priscilla N Kelly et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.